» Articles » PMID: 14755726

Presence of Dendritic Cells, MCP-1, and Activated Microglia/macrophages in Amyotrophic Lateral Sclerosis Spinal Cord Tissue

Overview
Journal Ann Neurol
Specialty Neurology
Date 2004 Feb 3
PMID 14755726
Citations 227
Authors
Affiliations
Soon will be listed here.
Abstract

Dendritic cells are potent antigen-presenting cells that initiate and amplify immune responses. To determine whether dendritic cells participate in inflammatory reactions in amyotrophic lateral sclerosis (ALS), we examined mRNA expression of dendritic cell surface markers in individual sporadic ALS (sALS), familial ALS (fALS), and nonneurological disease control (NNDC) spinal cord tissues using semiquantitative and real-time reverse transcription polymerase chain reaction (RT-PCR). Immature (DEC205, CD1a) and activated/mature (CD83, CD40) dendritic cell transcripts were significantly elevated in ALS tissues. The presence of immature and activated/mature dendritic cells (CD1a(+) and CD83(+)) was confirmed immunohistochemically in ALS ventral horn and corticospinal tracts. Monocytic/macrophage/microglial transcripts (CD14, CD18, SR-A, CD68) were increased in ALS spinal cord, and activated CD68(+) cells were demonstrated in close proximity to motor neurons. mRNA expressions of the chemokine MCP-1, which attracts monocytes and myeloid dendritic cells, and of the cytokine macrophage-colony stimulating factor (M-CSF) were increased in ALS tissues. The MCP-1 protein was expressed in glia in ALS but not in control tissues and was increased in the CSF of ALS patients. Those patients who progressed most rapidly expressed significantly more dendritic transcripts than patients who progressed more slowly. These results support the involvement of immune/inflammatory responses in amplifying motor neuron degeneration in ALS.

Citing Articles

Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller K, Chaytow H, Gillingwater T Nat Rev Neurol. 2025; 21(2):86-102.

PMID: 39743546 DOI: 10.1038/s41582-024-01049-4.


Immune mechanisms and shared immune targets in neurodegenerative diseases.

Weiner H Nat Rev Neurol. 2024; 21(2):67-85.

PMID: 39681722 DOI: 10.1038/s41582-024-01046-7.


Effect of fecal microbiota transplantation on patients with sporadic amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial.

Feng R, Zhu Q, Wang A, Wang H, Wang J, Chen P BMC Med. 2024; 22(1):566.

PMID: 39617896 PMC: 11610222. DOI: 10.1186/s12916-024-03781-6.


Gut microbiota immune cross-talk in amyotrophic lateral sclerosis.

Kaul M, Mukherjee D, Weiner H, Cox L Neurotherapeutics. 2024; 21(6):e00469.

PMID: 39510899 PMC: 11585889. DOI: 10.1016/j.neurot.2024.e00469.


Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.

Perrin S, Ladha S, Maragakis N, Rivner M, Katz J, Genge A PLoS Med. 2024; 21(10):e1004469.

PMID: 39480764 PMC: 11527214. DOI: 10.1371/journal.pmed.1004469.